Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone A, Krapcho M, et al. SEER cancer statistics review, 1975–2009 (vintage 2009 populations). Bethesda (MD): National Cancer Institute; 2012. p. 1975–2009.
   Google Scholar
• Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–2921.
   PubMed Web of Science ®Google Scholar
• Sohal DPS, Mangu PB, Khorana AA, et al. Metastatic pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016;34(23):2784–2796.
   PubMed Web of Science ®Google Scholar
• Yip D, Karapetis C, Strickland A, et al. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD002093. DOI:10.1002/14651858.CD002093.pub2.
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997 Jun;15(6):2403–2413.
   PubMed Web of Science ®Google Scholar
• Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006 Aug 20;24(24):3946–3952.
   PubMed Web of Science ®Google Scholar
• Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005 May 20;23(15):3509–3516.
   PubMed Web of Science ®Google Scholar
• Poplin E, Feng Y, Berlin J, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009 Aug 10;27(23):3778–3785.
   PubMed Web of Science ®Google Scholar
• Heinemann V, Labianca R, Hinke A, et al. Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol. 2007 Oct;18(10):1652–1659.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009 Nov 20;27(33):5513–5518.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017 Jan 24;389:1011–1024.
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007 May 20;25(15):1960–1966.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817–1825.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct 31;369(18):1691–1703.
   PubMed Web of Science ®Google Scholar
• Goldstein D, El-Maraghi RH, Hammel P, et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst. 2015 Feb;107(2):dju413-dju413.
   PubMedGoogle Scholar
• Waddell N, Pajic M, Patch A-M, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015 Feb 26;518(7540):495–501.
   PubMed Web of Science ®Google Scholar
• Vivaldi C, Caparello C, Musettini G, et al. First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: patients’ outcome and analysis of prognostic factors. Int J Cancer. 2016 Aug 15;139(4):938–945.
   PubMed Web of Science ®Google Scholar
• Tabernero J, Chiorean EG, Infante JR, et al. Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Oncologist. 2015;20(2):143–150.
   PubMed Web of Science ®Google Scholar
• Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33(8):828–833.
   PubMed Web of Science ®Google Scholar
• Le DT, Lutz E, Uram JN, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother. 2013;36(7):382.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–2465.
   PubMed Web of Science ®Google Scholar
• Middleton G, Silcocks P, Cox T, et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncol. 2014;15(8):829–840.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers. J Clin Oncol. 2016;34:195.
   Web of Science ®Google Scholar
• Kunk PR, Bauer TW, Slingluff CL, et al. From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. J Immunother Cancer. 2016;4(1):14.
   PubMed Web of Science ®Google Scholar
• Nagrial AM, Chin VT, Sjoquist KM, et al. Second-line treatment in inoperable pancreatic adenocarcinoma: a systematic review and synthesis of all clinical trials. Crit Rev Oncol Hematol. 2015 Dec;96(3):483–497.
   PubMed Web of Science ®Google Scholar
• Pelzer U, Schwaner I, Stieler J, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011 Jul;47(11):1676–1681.
   PubMed Web of Science ®Google Scholar
• Gill S, Ko Y-J, Cripps C, et al. PANCREOX: a randomized phase III study of fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol. 2016 Sep 12;34:3914–3920.
   PubMed Web of Science ®Google Scholar
• Chiorean EG, Von Hoff DD, Tabernero J, et al. Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. Br J Cancer. 2016;115(2):188–194.
   PubMed Web of Science ®Google Scholar
• Wang-Gillam A, Li C-P, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016 Feb 6;387(10018):545–557.
   PubMed Web of Science ®Google Scholar
• Heinemann V, Vehling-Kaiser U, Waldschmidt D, et al. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104). Gut. 2013 May;62(5):751–759.
   PubMed Web of Science ®Google Scholar
• Heestand GM, Murphy JD, Lowy AM. Approach to patients with pancreatic cancer without detectable metastases. J Clin Oncol. 2015;33(16):1770–1778.
   PubMed Web of Science ®Google Scholar
• Gandy RC, Barbour AP, Samra J, et al. Refining the care of patients with pancreatic cancer: the AGITG Pancreatic Cancer Workshop consensus. Med J Aust. 2016;204(11):419–422.
   PubMed Web of Science ®Google Scholar
• Gillen S, Schuster T, Meyer Zum Buschenfelde C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010 Apr 20;7(4):e1000267.
   PubMed Web of Science ®Google Scholar
• Schorn S, Demir IE, Reyes CM, et al. The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma–a systematic review and meta-analysis. Cancer Treat Rev. 2017;55:96–106.
   PubMed Web of Science ®Google Scholar
• Golcher H, Brunner TB, Witzigmann H, et al. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer. Strahlentherapie Onkologie. 2015;191(1):7–16.
   PubMed Web of Science ®Google Scholar
• Casadei R, Di Marco M, Ricci C, et al. Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which failed to achieve accrual targets. J Gastrointest Surg. 2015;19(10):1802–1812.
   PubMed Web of Science ®Google Scholar
• Sultana A, Smith CT, Cunningham D, et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer. 2007;96(8):1183–1190.
   PubMed Web of Science ®Google Scholar
• Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Ann Oncol. 2008;19(9):1592–1599.
   PubMed Web of Science ®Google Scholar
• Hammel P, Huguet F, Van Laethem J-L, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. Jama. 2016;315(17):1844–1853.
   PubMed Web of Science ®Google Scholar
• Katz MHG, Shi Q, Ahmad SA, et al. Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg. 2016;151(8):e161137.
   PubMed Web of Science ®Google Scholar
• Suker M, Beumer BR, Sadot E, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17(6):801–810.
   PubMed Web of Science ®Google Scholar
• Ducreux M, Cuhna AS, Caramella C, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(suppl 5):v56–v68.
   PubMed Web of Science ®Google Scholar
• Vernerey D, Huguet F, Vienot A, et al. Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP). Br J Cancer. 2016;115:281–289.
   PubMed Web of Science ®Google Scholar
• Mokdad AA, Minter RM, Zhu H, et al. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol. 2016;35(5):515–522.
   PubMedGoogle Scholar
• Perez K, Clancy TE, Mancias JD, et al. When, what, and why of perioperative treatment of potentially curable pancreatic adenocarcinoma. J Clin Oncol. 2016 ;35(5):485–489.
   Web of Science ®Google Scholar
• Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358(9293):1576–1585.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Mangu PB, Berlin J, et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016 Jul 20;34(21):2541–2556.
   PubMed Web of Science ®Google Scholar
• Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. Jama. 2007;297(3):267–277.
   PubMed Web of Science ®Google Scholar
• Neoptolemos J, Büchler M, Stocken D, et al. ESPAC-3 (v2): a multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol. 2009;27(18_suppl):LBA4505.
   Web of Science ®Google Scholar
• Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388(10041):248–257.
   PubMed Web of Science ®Google Scholar
• Nagrial A, Chang D, Nguyen N, et al. Adjuvant chemotherapy in elderly patients with pancreatic cancer. Br J Cancer. 2014;110(2):313–319.
   PubMed Web of Science ®Google Scholar
• Sinn M, Liersch T, Gellert K, et al. CONKO-005: adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeks—A prospective randomized phase III study. Am Soc Clin Oncol. 2015;4007–4007.
   Google Scholar
• Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491(7424):399–405.
   PubMed Web of Science ®Google Scholar
• Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer [Article]. Nature. 2016 Feb 24;531:47–52.
   PubMed Web of Science ®Google Scholar
• Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008 Sep 26;321(5897):1801–1806.
   PubMed Web of Science ®Google Scholar
• Witkiewicz AK, McMillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.
   PubMed Web of Science ®Google Scholar
• Wang L, Tsutsumi S, Kawaguchi T, et al. Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency. Genome Res. 2012 Feb;22(2):208–219.
   PubMed Web of Science ®Google Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013 Aug 22;500(7463):415–421.
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Itoh F, Nakamura H, et al. Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability. Cancer Res. 2001 Apr 1;61(7):3139–3144.
   PubMed Web of Science ®Google Scholar
• Bird N, Elmasry M, Jones R, et al. Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine‐based chemotherapy. Br J Surg. 2017;104(4):328–336.
   PubMed Web of Science ®Google Scholar
• Cheng H, Liu C, Jiang J, et al. Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients. Int J Cancer. 2017;140(10):2344–2350.
   PubMed Web of Science ®Google Scholar
• Lewis AR, Valle JW, McNamara MG. Pancreatic cancer: are” liquid biopsies” ready for prime-time? World J Gastroenterol. 2016;22(32):7175.
   PubMed Web of Science ®Google Scholar
• Gao Y, Zhu Y, Yuan Z. Circulating tumor cells and circulating tumor DNA provide new insights into pancreatic cancer. Int J Med Sci. 2016;13(12):902–913.
   PubMed Web of Science ®Google Scholar
• Lee B, Cohen J, Lipton LR, et al. Potential role of circulating tumor DNA (ctDNA) in the early diagnosis and post-operative management of localised pancreatic cancer. Am Soc Clin Oncol. 2017:4101–4101.
   Google Scholar
• Tutt A, Robson M, Garber JE, et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376(9737):235–244.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012 Jul 19;487(7407):330–337.
   PubMed Web of Science ®Google Scholar
• Le A-T, Tzeng C-WD. Does finding early recurrence improve outcomes, and at what cost? J Surg Oncol. 2016;114(3):329–335.
   PubMed Web of Science ®Google Scholar
• Bang Y-J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–697.
   PubMed Web of Science ®Google Scholar
• Chou A, Waddell N, Cowley M, et al. Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Genome Med. 2013;5(8):78.
   PubMed Web of Science ®Google Scholar
• Harder J, Ihorst G, Heinemann V, et al. Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. Br J Cancer. 2012;106(6):1033–1038.
   PubMed Web of Science ®Google Scholar
• Ardekani GS, Jafarnejad SM, Tan L, et al. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One. 2012;7(10):e47054.
   PubMed Web of Science ®Google Scholar
• Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR. Nature. 2012;483(7387):100–103.
   PubMed Web of Science ®Google Scholar
• Chantrill LA, Nagrial A, Johns A, et al. Clinical utilization of targetable molecular results in pancreatic cancer: longer-term outcomes from the Individualized Molecular Pancreatic Cancer Therapy (IMPACT) trial. Am Soc Clin Oncol. 2017;35:314.
   Google Scholar
• Pfau PR, Pleskow DK, Banerjee S, et al. Pancreatic and biliary stents. Gastrointest Endosc. 2013;77(3):319–327.
   PubMed Web of Science ®Google Scholar
• Dumonceau J-M, Tringali A, Blero D, et al. Biliary stenting: indications, choice of stents and results: European Society of Gastrointestinal Endoscopy (ESGE) clinical guideline. Endoscopy. 2012;44(03):277–298.
   PubMed Web of Science ®Google Scholar
• Nam HS, Kang DH. Current status of biliary metal stents. Clin Endosc. 2016;49(2):124–130.
   PubMedGoogle Scholar
• Stark A, Hines OJ, editors. Endoscopic and operative palliation strategies for pancreatic ductal adenocarcinoma. In: Seminars in oncology. WB Saunders. 2015;42(1):163–176.
   Google Scholar
• Mueller-Lissner S. Fixed combination of oxycodone with naloxone: a new way to prevent and treat opioid-induced constipation. Adv Ther. 2010 Sep;27(9):581–590.
   PubMed Web of Science ®Google Scholar
• Domínguez‐Muñoz JE. Pancreatic exocrine insufficiency: diagnosis and treatment. J Gastroenterol Hepatol. 2011;26(s2):12–16.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Bohlke K, Khorana AA, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33(6):654–656.
   PubMed Web of Science ®Google Scholar
• Janda M, Neale RE, Klein K, et al. Anxiety, depression and quality of life in people with pancreatic cancer and their carers. Pancreatology. 2017;17(2):321–327.
   PubMed Web of Science ®Google Scholar
• Sharpe M, Walker J, Hansen CH, et al. Integrated collaborative care for comorbid major depression in patients with cancer (SMaRT Oncology-2): a multicentre randomised controlled effectiveness trial. Lancet. 2014;384(9948):1099–1108.
   PubMed Web of Science ®Google Scholar
• Mueller TC, Burmeister MA, Bachmann J, et al. Cachexia and pancreatic cancer: are there treatment options? World J Gastroenterol. 2014;20(28):9361.
   PubMed Web of Science ®Google Scholar
• Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–495.
   PubMed Web of Science ®Google Scholar
• Bye A, Wesseltoft-Rao N, Iversen PO, et al. Alterations in inflammatory biomarkers and energy intake in cancer cachexia: a prospective study in patients with inoperable pancreatic cancer. Med Oncol. 2016;33(6):1–9.
   PubMed Web of Science ®Google Scholar
• Bachmann J, Ketterer K, Marsch C, et al. Pancreatic cancerrelated cachexia: influence on metabolism and correlation to weight loss and pulmonary function. BMC Cancer. 2009;9(1):255.
   PubMedGoogle Scholar
• Vujasinovic M, Valente R, Del Chiaro M, et al. Pancreatic exocrine insufficiency in pancreatic cancer. Nutrients. 2017;9(3):183.
   PubMed Web of Science ®Google Scholar
• Buffart LM, Kalter J, Sweegers MG, et al. Effects and moderators of exercise on quality of life and physical function in patients with cancer: an individual patient data meta-analysis of 34 RCTs. Cancer Treat Rev. 2017;52:91–204.
   PubMed Web of Science ®Google Scholar
• Courneya KS, Segal RJ, Mackey JR, et al. Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol. 2007;25(28):4396–4404.
   PubMed Web of Science ®Google Scholar
• Sandler C, Goldstein D, Horsfield S, et al. Treatment of Post-cancer fatigue Study (TOPS). J Pain Symptom Manage. 2017 May 11.
   PubMed Web of Science ®Google Scholar
• Mustian KM, Alfano CM, Heckler C, et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol. 2017;3:961.
   PubMed Web of Science ®Google Scholar
• Mizrahi D, Broderick C, Friedlander M, et al. An exercise intervention during chemotherapy for women with recurrent ovarian cancer: a feasibility study. Int J Gynecol Cancer. 2015;25(6):985–992.
   PubMed Web of Science ®Google Scholar
• Yee J, Davis GM, Beith JM, et al. Physical activity and fitness in women with metastatic breast cancer. J Cancer Surviv. 2014 Dec;8(4):647–656.
   PubMed Web of Science ®Google Scholar
• Neuzillet C, Vergnault M, Bonnetain F, et al. Rationale and design of the Adapted Physical Activity in advanced Pancreatic Cancer patients (APACaP) GERCOR (Groupe Coopérateur Multidisciplinaire en Oncologie) trial: study protocol for a randomized controlled trial. Trials. 2015;16(1):454.
   PubMed Web of Science ®Google Scholar
• Lira FS, De MM Antunes B, Seelaender M, et al. The therapeutic potential of exercise to treat cachexia. Curr Opin Support Palliat Care. 2015;9(4):317–324.
   PubMed Web of Science ®Google Scholar
• Beesley VL, Wockner LF, O’Rourke P, et al. Risk factors for current and future unmet supportive care needs of people with pancreatic cancer. A longitudinal study. Support Care Cancer. 2016 Aug;24(8):3589–3599.
   PubMed Web of Science ®Google Scholar